ReviewDrugs2003
CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.
Review in Drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 104 citations in OpenAlex.
- Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation.Health technology assessment (Winchester, England) · 2025Trial
- Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry.International urogynecology journal · 2014Trial
- Long-term clinical efficacy and cognitive impact of medications for overactive bladder related to the central nervous system.International urology and nephrology · 2026Article
- Alterations in the Cerebral Perivascular Space Network as a Potential Central Mechanism in Overactive Bladder: A Neuroimaging-Clinical Association Study.European urology open science · 2026Article
- Cigarette smoking, smoking cessation, and overactive bladder (OAB): a cross-sectional research of NHANES 2011 to 2018.BMC public health · 2025Article
- Fear of falling, gait capacity, and dual task performance in multiple sclerosis patients with and without neurogenic overactive bladder.Acta neurologica Belgica · 2025Article
- Secondary overactive bladder syndrome with restless legs syndrome following cerebral infarction: report of 2 cases.BMC geriatrics · 2025Article
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives.International neurourology journal · 2024Article
- Lower urinary tract dysfunction following stroke: From molecular mechanisms to clinical anatomy.Journal of biological methods · 2024Review
- Relationship between alcohol use and overactive bladder disease: a cross-sectional study of the NHANES 2005-2016.Frontiers in public health · 2024Article
- Bladder dysfunction following stroke: An updated review on diagnosis and management.Bladder (San Francisco, Calif.) · 2024Review
- Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB).Pharmaceuticals (Basel, Switzerland) · 2023Article
- Intrathecal Baclofen for Spasticity: Is There an Effect on Bladder Function? Report of Three Cases and Review of the Literature.Biomedicines · 2022Article
- Article
- Neurosonological Findings Related to Non-Motor Features of Parkinson's Disease: A Systematic Review.Brain sciences · 2021Review
- Involvement of interstitial cells of Cajal in bladder dysfunction in mice with experimental autoimmune encephalomyelitis.International urology and nephrology · 2017Article
- Sex difference in the contribution of GABAAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2017Article
- Role of cannabinoid receptor type 1 in tibial and pudendal neuromodulation of bladder overactivity in cats.American journal of physiology. Renal physiology · 2017Article
- Contribution of GABAA, Glycine, and Opioid Receptors to Sacral Neuromodulation of Bladder Overactivity in Cats.The Journal of pharmacology and experimental therapeutics · 2016Article
- Sympathetic β-adrenergic mechanism in pudendal inhibition of nociceptive and non-nociceptive reflex bladder activity.American journal of physiology. Renal physiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiology of overactive bladder (OAB) syndrome is complex, and involves both peripheral and CNS factors. Several CNS disorders are associated with OAB, e.g. stroke, spinal cord injury, Parkinson's disease and multiple sclerosis, and in each disorder the pathophysiology of OAB can be multifactorial. Irrespective of cause or pathophysiology of OAB, antimuscarinic drugs are the first line of pharmacological treatment. However, adverse effects and limited efficacy makes alternative therapeutic principles desirable. Most alternative drugs used for the treatment of OAB have a peripheral site of action, mainly affecting efferent or afferent neurotransmission or the detrusor muscle itself. New targets for pharmacological intervention may be found in the CNS. Several CNS transmitters/transmitter systems are known to be involved in micturition control, but few drugs with a defined CNS site of action (e.g. baclofen, imipramine and duloxetine) have been used for the treatment of voiding disorders. GABA, glutamate, opioid, serotonin, noradrenaline (norepinephrine), and dopamine receptors and mechanisms are known to influence micturition, and drugs influencing these systems could potentially be developed for the treatment of OAB. Preclinical studies in different animal models have shown that modulation of normal micturition and detrusor overactivity by drugs acting within the spinal cord or supraspinally is possible. Promising results have been obtained in such models, e.g. with drugs interfering with GABA mechanisms, serotonin 5-HT1A receptors, mu-opioid receptors and alpha-adrenoreceptors. However, considering the limited predictability of existing animal models for efficacy in humans, positive proof of concept studies in humans are mandatory. Such studies are scarce and further investigations are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.